We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

BioPerfectus Technologies

Bioperfectus Technologies Co., Ltd. is one of the leading molecular diagnostic solution providers in the global in-vi... read more Featured Products: More products

Download Mobile App





Bioperfectus Obtains CE Mark for SARS-CoV-2 Antigen Rapid Self-Test

By LabMedica International staff writers
Posted on 05 Jan 2022

Jiangsu Bioperfectus Technologies Co. More...

, Ltd. (Shanghai, China) has obtained CE Mark for its Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test).

The lateral flow test is intended for non-prescription home use with self-collected nasal swab specimens. It is used to detect symptomatic individuals who are suspected of COVID-19 or asymptomatic individuals who have had contact with confirmed COVID-19 patients but do not show any symptoms. It delivers fast results within 15 minutes and is able to detect asymptomatic cases as well as remain effective in the case of variants.

The Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit was previously available as a home test in the German and Austrian markets since May 20th, 2021. With the CE Mark, the test has received official approval following the traditional registration pathway and can now also be used in markets that have not established regulatory exemption pathways.

Related Links:
Jiangsu Bioperfectus Technologies Co., Ltd. 


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Clinical Chemistry Analyzer
Envoy 500+
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.